Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 135-142 , April 2005

Positron emission tomography and bone metastases

  • Ignac Fogelman, BSc, MD (FRCP)

      Affiliations

    • Division of Imaging, King’s College, London, United Kingdom.
    • Corresponding Author InformationAddress reprint requests to Ignac Fogelman, BSc, MD, FRCP, Department of Nuclear Medicine, Guy’s and St. Thomas’ NHS Hospital Trust, Guy’s Hospital, London SE1 9RT, UK.
    • ,
  • Gary Cook, MSc, MD (FRCP, FRCR)

      Affiliations

    • Department of Nuclear Medicine and PET, Royal Marsden Hospital, London, United Kingdom.
    • ,
  • Ora Israel, MD

      Affiliations

    • Rambam Medical Centre & Technicon-Israel Institute of Technology, Haifa, Israel.
    • ,
  • Hans Van der Wall, MBBS, PhD (FRACP)

      Affiliations

    • Department of Nuclear Medicine, Concord Hospital, Sydney, Australia.

References 

  1. Hetzel M , Hetzel J , Arslandemir C , et al.   Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer (Prospective study) . BMJ . 2004;328:1051–1052
  2. Schirrmeister H , Arslandemir C , Glatting G , et al.   Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer . Eur J Nucl Med Mol Imaging . 2004;31:964–968
  3. Dolan AL , Ryan PJ , Arden NK , et al.   The value of SPECT scans in identifying back pain likely to benefit from facet joint injection . Br J Rheumatol . 1996;35:1269–1273
  4. Ryan PJ , Evans PA , Gibson T , et al.   Chronic low back pain (Comparison of bone SPECT with radiography and CT) . Radiology . 1992;182:849–854
  5. Ryan PJ , Evans P , Gibson T , et al.   Osteoporosis and chronic back pain (A study with single-photon emission computed tomography bone scintigraphy) . J Bone Miner Res . 1992;7:1455–1460
  6. Schirrmeister H , Glatting G , Hetzel J , et al.   Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer . J Nucl Med . 2001;42:1800–1804
  7. Savelli G , Maffioli L , Maccauro M , et al.   Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions . Q J Nucl Med . 2001;45:27–37
  8. Cook GJ , Fogelman I . The role of nuclear medicine in monitoring treatment in skeletal malignancy . Semin Nucl Med . 2001;31:206–211
  9. Koizumi M , Matsumoto S , Takahashi S , et al.   Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer . Clin Nucl Med . 1999;24:15–20
  10. Blake GM , Park-Holohan SJ , Cook GJ , et al.   Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate . Semin Nucl Med . 2001;31:28–49
  11. Fogelman I . Skeletal uptake of diphosphonate (A review) . Eur J Nucl Med . 1980;5:473–476
  12. Schirrmeister H , Guhlmann A , Elsner K , et al.   Sensitivity in detecting osseous lesions depends on anatomic localization (Planar bone scintigraphy versus 18F PET) . J Nucl Med . 1999;40:1623–1629
  13. Hetzel M , Arslandemir C , Konig HH , et al.   F-18 NaF PET for detection of bone metastases in lung cancer (Accuracy, cost-effectiveness, and impact on patient management) . J Bone Miner Res . 2003;18:2206–2214
  14. Even-Sapir E , Metser U , Flusser G , et al.   Assessment of malignant skeletal disease (initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT) . J Nucl Med . 2004;45:272–278
  15. Lonneux M , Borbath II , Berliere M , et al.   The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer . Clin Positron Imaging . 2000;3:45–49
  16. Ohta M , Tokuda Y , Suzuki Y , et al.   Whole body PET for the evaluation of bony metastases in patients with breast cancer (Comparison with 99Tcm-MDP bone scintigraphy) . Nucl Med Commun . 2001;22:875–879
  17. Yang SN , Liang JA , Lin FJ , et al.   Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer . J Cancer Res Clin Oncol . 2002;128:325–328
  18. Moon DH , Maddahi J , Silverman DH , et al.   Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma . J Nucl Med . 1998;39:431–435
  19. Gallowitsch HJ , Kresnik E , Gasser J , et al.   F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma (A comparison to conventional imaging) . Invest Radiol . 2003;38:250–256
  20. Cook GJ , Houston S , Rubens R , et al.   Detection of bone metastases in breast cancer by 18FDG PET (Differing metabolic activity in osteoblastic and osteolytic lesions) . J Clin Oncol . 1998;16:3375–3379
  21. Garcia JR , Simo M , Perez G , et al.   99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients (Different affinity between lytic and sclerotic bone metastases) . Eur J Nucl Med Mol Imaging . 2003;30:1714
  22. Clavo AC , Brown RS , Wahl RL . Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia . J Nucl Med . 1995;36:1625–1632
  23. Stafford SE , Gralow JR , Schubert EK , et al.   Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy . Acad Radiol . 2002;9:913–921
  24. Mortimer JE , Dehdashti F , Siegel BA , et al.   Metabolic flare (Indicator of hormone responsiveness in advanced breast cancer) . J Clin Oncol . 2001;19:2797–2803
  25. Yeh SD , Imbriaco M , Larson SM , et al.   Detection of bony metastases of androgen-independent prostate cancer by PET-FDG . Nucl Med Biol . 1996;23:693–697
  26. Shreve PD , Grossman HB , Gross MD , et al.   Metastatic prostate cancer (Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose) . Radiology . 1996;199:751–756
  27. Morris MJ , Akhurst T , Osman I , et al.   Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer . Urology . 2002;59:913–918
  28. Marom EM , McAdams HP , Erasmus JJ , et al.   Staging non-small cell lung cancer with whole-body PET . Radiology . 1999;212:803–809
  29. Durski JM , Srinivas S , Segall G . Comparison of FDG-PET and bone scans for detecting skeletal metastases in patients with non-small cell lung cancer . Clin Positron Imaging . 2000;3:97–105
  30. Bury T , Barreto A , Daenen F , et al.   Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer . Eur J Nucl Med . 1998;25:1244–1247
  31. Gayed I , Vu T , Johnson M , et al.   Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer . Mol Imaging Biol . 2003;5:26–31
  32. Metser U , Lerman H , Blank A , et al.   Malignant involvement of the spine (Assessment by 18F-FDG PET/CT) . J Nucl Med . 2004;45:279–284
  33. Moog F , Kotzerke J , Reske SN . FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma . J Nucl Med . 1999;40:1407–1413
  34. Durie BG , Waxman AD , D’Agnolo A , et al.   Whole-body (18)F-FDG PET identifies high-risk myeloma . J Nucl Med . 2002;43:1457–1463
  35. Schirrmeister H , Bommer M , Buck AK , et al.   Initial results in the assessment of multiple myeloma using 18F-FDG PET . Eur J Nucl Med Mol Imaging . 2002;29:361–366
  36. Israel O , Militianu D , Goldberg A , et al.   PET/CT assessment of bone metastases—FDG avidity and CT patterns before and after treatment . J Nucl Med . 2004;45:79P; (abstr)

PII: S0001-2998(04)00077-7

doi: 10.1053/j.semnuclmed.2004.11.005

Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 135-142 , April 2005

Article Tools

* Image Usage & Resolution